Correlation Analysis of Plasma Fatty Acid Levels in Patients with Tumor and Abnormal Savda in Uyghur Medicine
MAMTIMIN Batur1, SUN Feng2, KELIMU Alimujiang3, KONG Bin1, GONG Can1, UPUR Halmurat4
1. College of Pharmacy, Xinjiang Medical University, Urumqi 830011, China;
2. The Fourth Affiliated Hospital, Xinjiang Medical University, Urumqi 830011, China;
3. Department of Neurosurgery, Shanghai East Hospital Affiliated to Tongji University, Shanghai 200120, China;
4. College of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830011, China
Abstract:To investigate the plasma fatty acid metabolism of different cancer patients with abnormal Savda in Uyghur medicine and analyze its common features, the plasma fatty acid concentration was tested by the gas chromatography (GC) from 122 cases of cancer patients with abnormal Savda including 25 cases of esophageal cancer, 20 cases of colorectal cancer, 33 cases of lung cancer, 20 cases of breast cancer and 24 cases of gastric cancer, and 35 healthy volunteers as a control group. The spectral profiles were subjected to a t-test for statistical significance. The results show that compared to the healthy group, the patients of esophageal cancer, colorectal cancer, lung cancer, breast cancer and gastric cancer with abnormal Savda suffer a high concentration of myristic acid; the patients of esophageal cancer, lung cancer, breast cancer and gastric cancer with abnormal Savda suffer a high concentration of palm acid; the patients of colorectal cancer, lung cancer and breast cancer with abnormal Savda suffer a high concentration of palmitic acid; the patients of esophageal cancer, lung cancer and gastric cancer with abnormal Savda suffer a low concentration of linoleic acid; the patients of esophageal cancer, colorectal cancer, lung cancer and breast cancer with abnormal Savda suffer a high concentration of oleic acid; the patients of breast cancer patients with abnormal Savda suffer a low concentration of stearic acid; the patients of esophageal cancer and gastric cancer with abnormal Savda suffer a low concentration of arachidonic acid; the patients of breast cancer patients with abnormal Savda suffer a high concentration of EPA, but the patients of gastric cancer with abnormal Savda suffer a low concentration of EPA; the patients of esophageal cancer, lung cancer and breast cancer with abnormal Savda suffer a high concentration of arachidic acid; the patients of esophageal cancer and gastric cancer with abnormal Savda suffer a high concentration of DHA. It is concluded that these findings suggest that different tumor patients with abnormal Savda see some common characteristics, and also significant differences.
[1] 易沙克江. 中国医学百科全书. 维吾尔医分卷(维吾尔文)[M]. 乌鲁木 齐: 新疆科技卫生出版社, 1985. Ishakjan. The encyclopedia of Uyghur traditional medicine[M]. Urumqi: Xinjiang Science and Technology Publishing House, 1985.
[2] 买买提明·沙比尔. 维吾尔医学诊断学[M]. 乌鲁木齐: 新疆科技卫生 出版社, 1993. Sabir Mamatimin. Diagnostics of Uyghur medicine[M]. Urumqi: Science and Technology Publishing Company in Xinjiang, 1993.
[3] 哈木拉提·吾甫尔. 维吾尔医学体液论及其现代研究[M]. 乌鲁木齐: 新疆科技卫生出版社, 2003. Halmurat Upur. Therapy of Mizaj and Hilit in Uyghur medicine and modern study[M]. Urumqi: Science and Technique Publishing Company in Xinjiang, 2003.
[4] 库热西江·托乎提, 阿不都热依木·玉素甫, 哈木拉提·吾甫尔, 等. 维 吾尔医正常体液与异常体液分型比较研究[J]. 中国民族医药杂志, 2004(3): 3-4 Tohti Kurash, Yusup Abdurehim, Upur Halmurat, et al. Classify study on normal and unnormal physique fluid of Uyghur raditional medicine[J]. Journal of Medicine & Pharmacy of Chinese Minorities, 2004(3): 3-4.
[5] 哈木拉提·吾甫尔, 阿不都热依木·玉苏甫, 吐尔逊·吾甫尔, 等. 维医 异常体液分型与年龄、性别关系的探讨[J]. 中国民族民间医药杂志, 2003(2): 84-86. Upur Halmurat, Yusup Abdurehim, Upur Tursun, et al. An approach to the relation of types of abnormal body-liquid and sexuality or age in Uyghur nationality medicine[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy, 2003(2): 84-86.
[6] 哈木拉提·吾甫尔, 阿不都热依木·玉苏甫. 维吾尔医异常黑胆质新论[M]. 乌鲁木齐: 新疆人民出版社, 2009. Upur Halmurat, Yusup Abdurehim. The new theory of abnormal savda Hilit in Uyghur medicine[M]. Urumqi: Xinjiang People's Publishing House, 2009.
[7] Torelli G F, Cascino A, Muscaritoli M, et al. Energy metabolism in cancer patients[J]. Minerva Gastroenterologicae Dietologica, 1997, 43(4): 183-188.
[8] Bradbury K E, Skeaff C M, Green T J, et al. The serum fatty acids myristic acid and linoleic acid are better predictors of serum cholesterol concentrations when measured as molecular percentages rather than as absolute concentrations[J]. The American Journal of Clinical Nutrition, 2010, 91(2): 398-405.
[9] Zöllner A, Dragan C A, Pistorius D, et al. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid[J]. Biological Chemistry, 2009, 390(4): 313-317.
[10] Mamtimin B, Upur B, Hao F, et al. Plasma metabonomic analysis with 1H nuclear magnetic resonance revealing the relationship of different tumors and the disease homology theory of traditional Uyghur medicine[J]. Chinese Journal of Integrative Medicine, 2011, 17(2): 111-115.
[11] 艾斯克尔·吐拉洪, 哈木拉提·吾甫尔, 豪富华, 等. 基于NMR的维吾 尔医异常黑胆质型肿瘤患者血浆代谢组学分析[J]. 科技导报, 2009, 27(13): 27-31. Turahun Askar, Upur Halmurat, Hao Fuhua, et al. Metabonomic studies on abnormal savda syndrome patients with neoplasm using nmr spectroscopy[J]. Science & Technology Review, 2009, 27(13): 27-31.
[12] 巴吐尔·买买提明, 哈木拉提·吾甫尔, 豪富华. 异常黑胆质型与非异 常黑胆质型肿瘤患者血浆代谢组学差异分析[J]. 科技导报, 2009, 27 (20): 39-43. Mamtimin Batur, Upur Halmurat, Hao Fuhua. Metabonomic differences of plasma between abnormal Savda and Unsavda syndrome neoplasm patients[J]. Science & Technology Review, 2009, 27(20): 39-43.
[13] Calder P C. Polyunsaturated fatty acids, inflammation, and immunity[J]. Lipids, 2001, 36(9): 1007-1024.
[14] 陈龙, 王丙云, 毛鑫智. 动物肝损伤组织花生四烯酸代谢物水平的变 化[J].南京师范大学学报: 自然科学版, 2000, 24(1): 62-66. Chen Long, Wang Bingyun, Mao Xinzhi. Changes of arachidonic acid metabolites of liver injury tissue in animals[J]. Journal of Nanjing Normal University: Natural Science Edition, 2000, 24(1): 62-66.
[15] 刘冀红, 曹新伟. n-3多不饱和脂肪酸在肿瘤防治中的意义[J]. 肠外 与肠内营养, 2004, 11(1): 55-57. Liu Jihong, Cao Xinwei. Effects of n-3 fatty acids on prevention and therapy of tumor[J]. Parenteral & Enteral Nutrition, 2004, 11(1): 55-57.